Gilead Sciences (NASDAQ:GILD - Get Free Report) is expected to be announcing its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $2.16 per share and revenue of $7.4151 billion for the quarter. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 EPS. On average, analysts expect Gilead Sciences to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Gilead Sciences Stock Down 2.1%
NASDAQ GILD opened at $121.46 on Thursday. The firm has a market cap of $150.71 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 0.85 and a beta of 0.34. Gilead Sciences has a one year low of $86.08 and a one year high of $124.61. The stock's 50 day simple moving average is $115.38 and its 200 day simple moving average is $110.78. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.
Gilead Sciences Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences's dividend payout ratio is 62.95%.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on GILD shares. Citigroup increased their price target on Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Wednesday, October 8th. Cantor Fitzgerald upped their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $121.14.
Get Our Latest Research Report on GILD
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,500 shares of company stock worth $8,281,540 in the last three months. Insiders own 0.27% of the company's stock.
Institutional Trading of Gilead Sciences
Several hedge funds have recently added to or reduced their stakes in the business. Evergreen Capital Management LLC raised its stake in Gilead Sciences by 16.4% during the 2nd quarter. Evergreen Capital Management LLC now owns 24,072 shares of the biopharmaceutical company's stock worth $2,669,000 after buying an additional 3,393 shares during the period. Strategic Investment Advisors MI raised its stake in Gilead Sciences by 108.9% during the 2nd quarter. Strategic Investment Advisors MI now owns 6,025 shares of the biopharmaceutical company's stock worth $668,000 after buying an additional 3,141 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in Gilead Sciences by 1.4% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 2,227,558 shares of the biopharmaceutical company's stock worth $247,158,000 after buying an additional 31,793 shares during the period. 44 Wealth Management LLC raised its stake in Gilead Sciences by 3.7% during the 2nd quarter. 44 Wealth Management LLC now owns 2,923 shares of the biopharmaceutical company's stock worth $324,000 after buying an additional 105 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Gilead Sciences by 62.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 47,800 shares of the biopharmaceutical company's stock worth $5,300,000 after buying an additional 18,390 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
